News
SELB
1.280
-1.54%
-0.020
BRIEF-Selecta Biosciences - On June 22, Co Received Letter From Nasdaq Notifying Co It Regained Compliance With $1 Per Share Minimum Bid Price Requirement
BRIEF-Selecta Biosciences - On June 22, Co Received Letter From Nasdaq Notifying Co It Regained Compliance With $1 Per Share Minimum Bid Price Requirement
Reuters · 6d ago
Expert Ratings for Selecta Biosciences
Over the past 3 months, 4 analysts have published their opinion on Selecta Biosciences (NASDAQ:SELB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trad...
Benzinga · 06/21 15:08
HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating
MT Newswires · 06/21 08:30
BioMarin (BMRN) Stock Jumps 5.4%: Will It Continue to Soar?
BioMarin (BMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 06/20 11:43
Insider Buy: Selecta Biosciences
MT Newswires · 06/15 16:26
Some Analysts Just Cut Their Selecta Biosciences, Inc. (NASDAQ:SELB) Estimates
One thing we could say about the analysts on Selecta Biosciences, Inc. ( NASDAQ:SELB ) - they aren't optimistic, having...
Simply Wall St. · 06/14 12:59
Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating
MT Newswires · 06/14 09:07
BRIEF-Selecta Biosciences Announces Partnership Advancements And Clinical Trial Updates
reuters.com · 06/13 11:36
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates
-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their option periods under the agreement to Q1 2...
GlobeNewswire · 06/13 11:30
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
Why Wall Street Doubts This Biotech Penny Stock Will Be Delisted
The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.
TheStreet.com · 06/10 19:26
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Benzinga · 06/10 16:07
Bluebird Bio drives gene therapy stocks higher after FDA review
A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE)
Seekingalpha · 06/07 19:59
SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock
Benzinga · 06/06 18:47
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022
Upgrades
Benzinga · 06/06 15:12
SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target
MT Newswires · 06/06 07:38
BRIEF-Selecta Biosciences Inc Received Notice From Nasdaq It Is No Longer In Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq
reuters.com · 06/03 20:35
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 06/02 11:24
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).
Benzinga · 06/02 10:55
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and m...
GlobeNewswire · 05/17 12:00
More
Webull provides a variety of real-time SELB stock news. You can receive the latest news about Selecta Biosci through multiple platforms. This information may help you make smarter investment decisions.
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. It enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.